New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease

ROCKVILLE, Md., Oct. 5, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new research paper was published demonstrating Thymosin Beta 4's (Tβ4) positive effects on animal models related to Alzheimer's Disease.

Researchers initially conducted behavior tests to assess learning, memory, anxiety and depression in mouse models expressing a human amyloid precursor protein and a mutant human presenilin 1, both of which are mutations associated with early-onset Alzheimer's Disease in humans.  According to the researchers, among other findings, Tβ4 over-expression in the mouse models alone showed less amyloid beta peptide, or amyloid deposits, which correlates with the clinical status of the patient. The research team also observed that over-expression of Tβ4 improved neuronal function and cognitive behavior performance and displayed anti-depressant-like effects. In the study, Tβ4 down regulated certain known inflammatory pathways, while other drug combinations did not, in particular NF-κB signaling.

"This study strongly supports Tβ4's previously demonstrated effects on certain neurological disorders and appears to do so by down-regulating NF-κB (among other inflammatory pathways), an inflammatory cytokine that has been shown to play a significant role in a number of neurological and cardiovascular injuries and diseases.  Its antidepressant-like effect was also notable and illustrated the possible link between Alzheimer's and depression.  I am encouraged that yet another independent study has shown Tβ4's potential role in treating serious neurological diseases such as Alzheimer's Disease," stated Dr. Allan L. Goldstein, Chairman Emeritus of Department of Biochemistry and Molecular Medicine at The George Washington University School of Medicine and RegeneRx's chairman and chief scientific advisor. 

The study, Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice, was published by Wang et. al, in the Journal of Neuroinflammation, doi.org/10.1186/s12974-021-02166-3.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac/neuro and dermal indications, four active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and the EU, and has patents and patent applications covering its products in many countries throughout the world.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  Forward-looking statements in this press release include but are not limited to statements from us or within research published by third parties. There can be no assurance that positive results from any research or clinical trial by the Company, its collaborators, or independent parties in the U.S. or any other country will result in subsequent clinical confirmation or future value.  There can also be no assurance that any of the Company's drug candidates will result in any approved products in the U.S. or any other country.  Please view risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2020, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE RegeneRx Biopharmaceuticals, Inc.

Related Links

http://www.regenerx.com